Drug stocks give FTSE a shot in the arm

clock

The FTSE 100 is off to a good start to the week with gains of 12.5 points, or 0.23%, to 5,544.1, with drug stocks leading the advance in response to news a US judge has upheld key patents on Pfizer's Lipitor cholesterol drug.

AstraZeneca, which makes the Crestor cholesterol treatment, has risen 65p, or 2.37%, to 2,812p, while GlaxoSmithKline has gained 30p, or 2.05%, to 1,490p, as the US ruling handed Pfizer patent protection on the world's best-selling drug until June 2011, dealing a blow to generic drug makers. Elsewhere, Kazakhstan miner Kazakhmys, entering the FTSE 100 for the first time since its October flotation, has fallen 8p, or 1.16%, to 680p, after it said copper cathode production in the first nine months of the year was in line with expectations. Housebuilder Persimmon, which is also making its ...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment

NextWealth MD Hopkins on staying ahead of advice sector changes, data challenges and flattening MPS fees

NextWealth MD Hopkins on staying ahead of advice sector changes, data challenges and flattening MPS fees

Making technology work better

Katrina Lloyd
clock 03 July 2025 • 9 min read
IFAs look to boost clients' private markets exposure

IFAs look to boost clients' private markets exposure

Expect increase in stock market volatility

Jen Frost
clock 02 July 2025 • 2 min read
Winds of change: Private markets access for retail investors

Winds of change: Private markets access for retail investors

Investing in LTAFs, accessibility aside, needs careful consideration

Dorian Hughes
clock 02 July 2025 • 5 min read